MedTrace Logo

Artificial Intelligence Assisted Breast Ultrasound in Breast Cancer Screening

NCT06521788 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21790

Last updated 2024-07-26

No results posted yet for this study

Summary

AIBU is a randomized, open-label study assessing the effectiveness of an articificial intelligence-assisted breast ultrasound breast cancer screening strategy compared to standard screening (according to the current local guidelines in each participating area) in detecting late-stage breast cancers.

Conditions

Interventions

DEVICE

AI-assisted breast ultrasound

AI-assisted breast ultrasound in community-based breast cancer screening

DEVICE

Routine breast ultrasound

Routine breast ultrasound conducted by primary care physicians

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Ying Zheng · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2023-08-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06521788 on ClinicalTrials.gov